CAJ | 학술논문

目的：进行吉非替尼治疗老年晚期非小细胞肺癌的疗效和毒性反应的临床研究。方法102例晚期非小细胞肺癌，其中52例给予吉非替尼150mg口服，每日1次，每28天重复。50例予单药吉西他滨1000mg／m2，d1，d8，d15，每28天重复。结果吉非替尼组CR、PR、SD、有效率、疾病控制率、1年生存率分别为3．85％，21．15％，38．46％，38．46％，25．00％，64．50％和28．85％。吉西他滨组CR、PR、SD、有效率、疾病控制率、1年生存率分别为0，24％，32％，24％，56％和26％。两者之间无统计学差异。吉非替尼治疗常见的毒副作用为皮疹和腹泻，总的皮疹发生率为46．15％，腹泻发生率为26．9％，未见间质性肺病和常见的血液学毒性出现。而吉西他滨组的不良反应主要为骨髓抑制和消化道反应。在血液学毒性方面吉西他滨明显高于吉非替尼组，具有统计学差异（ P＜0．05）。结论吉非替尼和吉西他滨单药治疗老年非小细胞肺癌疗效确切并相当。吉非替尼不仅延长了患者的生存，而且不良反应较轻，值得在临床老年非小细胞肺癌中应用。
목적：진행길비체니치료노년만기비소세포폐암적료효화독성반응적림상연구。방법102례만기비소세포폐암，기중52례급여길비체니150mg구복，매일1차，매28천중복。50례여단약길서타빈1000mg／m2，d1，d8，d15，매28천중복。결과길비체니조CR、PR、SD、유효솔、질병공제솔、1년생존솔분별위3．85％，21．15％，38．46％，38．46％，25．00％，64．50％화28．85％。길서타빈조CR、PR、SD、유효솔、질병공제솔、1년생존솔분별위0，24％，32％，24％，56％화26％。량자지간무통계학차이。길비체니치료상견적독부작용위피진화복사，총적피진발생솔위46．15％，복사발생솔위26．9％，미견간질성폐병화상견적혈액학독성출현。이길서타빈조적불량반응주요위골수억제화소화도반응。재혈액학독성방면길서타빈명현고우길비체니조，구유통계학차이（ P＜0．05）。결론길비체니화길서타빈단약치료노년비소세포폐암료효학절병상당。길비체니불부연장료환자적생존，이차불량반응교경，치득재림상노년비소세포폐암중응용。
Objectives To observe the efficacy and toxic of between gefitinib and gemcitabine in treatment of elder -patient with advanced non-small cell lung cancer.Methods 102 elderly patients with advanced non-small cell lung cancer 52 of them were trea-ted with gefitinib at the dose of 150mg p.o.per day, every 28 days.50 of them were treated with gemcitabine 1000mg/m2 on day 1, 8,15,every 28 days.Results Gefitinib group CR.PR.SD.PD.response rate.1-year survival rate was3.85%,21.15%,38.46%, 38.46%,25.00%,and 28.85%.Gemcitabine group CR.PR.SD.PD.response rate.1-year survival rate was 0%,24%,32%, 24%,and 26%.There was no statistical significance in two groups effeciency .Main adverse effects of gefitinib were generally mild (grade I or II),including shin rash 46.15%),diarrhea(26.90%).Main adverse effects of gemcitabine were Bone marrow suppres-sion and Gastrointestinal reactions .The Bone marrow suppression and Gastrointestinal reactions of two groups were statistical signifi -cance (P<0.05).Conclusions Gefitinib and gemcitabine are not only effective in the first line treatment of elderly patients with advanced NSCLC.The treatment with gefitinib in advanced stage small cell lung cancer is effective and safe .All the old patients have slight adverse sides and well compliance and tolerability .